# Efficacy and Safety of a Neoadjuvant Treatment in Pancreatic Cancer

> **NCT01389440** · PHASE2 · COMPLETED · sponsor: **Grupo Espanol Multidisciplinario del Cancer Digestivo** · enrollment: 24 (actual)

## Conditions studied

- Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** Gemcitabine and Erlotinib

## Key facts

- **NCT ID:** NCT01389440
- **Lead sponsor:** Grupo Espanol Multidisciplinario del Cancer Digestivo
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2016-11
- **Final completion:** 2017-01-22
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2018-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01389440

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01389440, "Efficacy and Safety of a Neoadjuvant Treatment in Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01389440. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*